Is amlodipine preferred over felodipine as the first-line calcium-channel blocker for hypertension and chronic stable angina?

Amlodipine versus Felodipine for Hypertension and Chronic Stable Angina

Amlodipine is preferred over felodipine as the first-line dihydropyridine calcium channel blocker for both hypertension and chronic stable angina, based on superior pharmacokinetic properties, better adherence, and more consistent 24-hour blood pressure control.

Rationale for Preferring Amlodipine

Pharmacokinetic Superiority

Amlodipine demonstrates significantly better pharmacokinetic properties that translate into clinical advantages 1, 2:

• Longer half-life: 35-50 hours versus felodipine's shorter duration
• Superior trough-to-peak ratio: 67% for amlodipine versus only 37% for felodipine 2
• More consistent drug levels: Less variability in plasma concentrations across the 24-hour dosing interval
• Sustained effect: Blood pressure control maintained even if a dose is missed 3

Clinical Efficacy Differences

While both drugs are effective, amlodipine shows measurable advantages:

For Hypertension:

• Nighttime blood pressure control: Amlodipine reduces nighttime systolic (p=0.026) and diastolic (p=0.019) blood pressure more effectively than felodipine 4
• 24-hour ambulatory monitoring: More consistent hypotensive effect across the entire dosing interval 2
• Response rates: 50% of patients responded to amlodipine versus 33% to felodipine after 4 weeks (p=0.013) 4
• Lower trough blood pressure: Better blood pressure values at 24 hours post-dose 2

For Chronic Stable Angina:

• Both drugs show equivalent antianginal efficacy in head-to-head trials 5
• Similar reductions in ischemic episodes (2.3 vs 2.4 episodes/24h) and anginal attacks (4.7 vs 4.3/week) 5
• Equivalent effects on ST-segment depression and nitrate consumption 5

Tolerability and Adherence

Amlodipine demonstrates superior real-world performance:

• 21% lower discontinuation rate compared to felodipine over 1 year in older adults 6
• Better early adherence: Only 20% discontinued after one prescription versus 30% with felodipine 6
• Fewer side effects: Significantly less headache and flushing compared to felodipine (p<0.05) 7
• Once-daily dosing with forgiveness: The long half-life provides protection even with occasional missed doses 3

Guideline Context

Current guidelines treat dihydropyridine calcium channel blockers as a class 8, 9, 10, listing both amlodipine and felodipine with identical dosing (5-10 mg once daily) and side effects (headache, edema). However, they note that "amlodipine and felodipine are reasonably well tolerated by patients with mild LV dysfunction" 9.

The 2024 ESC guidelines emphasize that "there is no robust evidence from direct comparisons that some antianginal drugs are more effective than others for improving symptoms" 10, but this refers to class-level comparisons, not within-class differences.

Practical Algorithm for Selection

Choose Amlodipine when:

• Initiating dihydropyridine therapy for hypertension or angina
• Patient has adherence concerns or complex medication regimens
• Nighttime blood pressure control is important
• Patient is elderly (better adherence data) 6
• Cost is similar between agents

Consider Felodipine only when:

• Amlodipine causes intolerable side effects (though less likely based on evidence)
• Specific formulary restrictions mandate its use
• Patient has documented good response to felodipine already

Important Caveats

Common to Both Drugs:

• Avoid in severe heart failure: Both can worsen outcomes in patients with reduced ejection fraction 11
• Side effects: Peripheral edema, headache, dizziness (though less with amlodipine) 8, 9, 7
• No mortality benefit: Neither drug improves survival in stable angina without heart failure 11
• Drug interactions: Both metabolized by CYP3A4; avoid with ivabradide due to bradycardia risk 11

Dosing Considerations:

• Start with 5 mg once daily for both drugs
• Titrate to 10 mg if needed for blood pressure or symptom control
• Side effects more common at 10 mg dose 3

Evidence Quality Assessment

The preference for amlodipine is based on:

• Multiple head-to-head RCTs showing pharmacokinetic and clinical advantages 7, 5, 4, 2
• Large real-world adherence study in older adults 6
• Consistent findings across different endpoints (ambulatory BP, nighttime control, adherence)

While guidelines list both as equivalent options, the granular evidence favors amlodipine for superior 24-hour control, better tolerability, and improved real-world adherence—factors that ultimately determine long-term cardiovascular outcomes.